New evidence from recently completed clinical studies performed with nebivolol, a highly
selective beta‐1 β‐blocker, endowed with additional vasodilating activity mediated by nitric …

Nebivolol is a new and selective β 1‐adrenergic receptor antagonist whose haemodynamic
profile is different from that of classical β‐blockers. The blood pressure lowering effects of …

Background Nebivolol represents a therapeutic class of beta blockers with high beta 1
selectivity and modulatory effect on vascular reactions by releasing nitric oxide (NO) from …

β-blockers are among the most widely used drugs in the prevention and treatment of
cardiovascular disease, although they are associated with increased peripheral resistance …

Nebivolol is a cardioselective lipophilic β-blocker devoid of intrinsic sympathomimetic and
membrane-stabilizing actions. The pharmacological profile differs from that of conventional …

Nebivolol is a new selective β1-adrenergic blocking agent, that possesses a peculiar
pharmacodynamic profile and an original chemical structure, by which it differs from …

Nebivolol is a novel beta1-blocker with a greater degree of selectivity for beta1-adrenergic
receptors than other agents in this class and a nitric oxide (NO)-potentiating, vasodilatory …

Nebivolol is a third generation beta-blocker, which can be distinguished from other beta-
blockers by its hemodynamic profile. It combines beta-adrenergic blocking activity with a …

Nebivolol (Bystolic®) is a cardioselective beta 1 (β1)‐adrenergic receptor blocker with
endothelium‐dependent vasodilating properties. The endothelium‐dependent relaxation …

Nebivolol is a vasodilating β-blocker, which can be distinguished from other β-blockers by its
haemodynamic profile. It combines β-adrenergic blocking activity with a vasodilating effect …